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: chenxi@implad.aAbstract This study was to determine tissue distribution and pharmacokinetics of mPEG-
scutellarin prodrug (7e), a chemical entity previously shown to have a beneﬁcial effect in cerebral
ischemia/reperfusion (I/R) injury. After injecting scutellarin or prodrug 7e, the concentrations of
scutellarin and 7e in tissues were determined and the pharmacokinetic parameters were calculated.
The results showed that the distribution of scutellarin in tissues was enhanced by PEGylation. The
distribution of 7e in brain was approximately 2.1-fold higher than that of scutellarin, indicating
that PEGylation increased the brain penetration of scutellarin. We conclude that 7e could exert
more effective protection on cerebral I/R injury in mice. This study also provided a simple and
convenient strategy to identify novel drugs with potential protective function for I/R injury in mice.
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Scutellarin (40,5,6-trihydroxyﬂavone-7-glucuronide) (Fig. 1) is
the major active component of traditional Chinese herb,
Erigeron breviscapus (Vant.) Hand-Mazz., which has been
used to treat acute cerebral infarction and paralysis induced
by cerebrovascular diseases such as hypertension, cerebral
thrombosis, and cerebral hemorrhage in China since 19841–3.
Although scutellarin has been clinically used for a long time, its
low solubility, poor bioavailability and short half-life in vivo limit
its clinical application4,5. Numerous efforts6–10 have been made
to improve the clinical usefulness of scutellarin. PEGylation has
been recognized as a promising strategy. PEGylation may extend
the retention time in body, enhance distribution into tissues, dec-
rease adverse effects, and increase resistance to degradation11–14.
These advantages generally improve patient compliance15.
In a previous study1, ﬁfteen PEGylated scutellarin prodrugs
were designed and synthesized. Four prodrugs were selected for
exploration of their activities according to water solubility and
protective effect on cerebral I/R injury. The protective effect of
the prodrugs on cerebral I/R injury was explored through a rat
middle cerebral artery occlusion (MCAO) model. The prodrug
7e (Fig. 1) exhibited a 7,000-fold increase in water solubility over
that of scutellarin, reduced infarct area from 27.2 to 12.2%
(33.3% for the control) and decreased the neurological deﬁcit
score from 2.77 to 1.32 (2.85 for the control). The data indicated
that the prodrug 7e had a protective effect on ischemic injury
induced by cerebral I/R in rats when compared with scutellarin.
Moreover, the pharmacokinetics of 7e and scutellarin revealed a
slower elimination of 7e in blood.
However, no comprehensive analysis of the protective effect
of 7e on cerebral I/R injury was reported. The investigation of
its distribution in tissues, especially in brain is highly desirable
to determine if slow elimination of 7e in blood can promote
better accessibility to its targets to validate its ability to protect
the brain from cerebral I/R injury.2. Materials and methods
2.1. Reagents and chemicals
7e (purity498%, determined by HPLC-UV-ELSD) was sepa-
rated and puriﬁed and its structure was conﬁrmed by 1H and
13C NMR spectroscopy. Scutellarin and rutin (IS) standards
were obtained from the National Institute for the Control
of Pharmaceutical and Biological Products (Beijing, China).
Acetonitrile was LC-grade and purchased from Merck. Deio-
nized water was prepared with a Milli-Q system (Millipore,
France). Other reagents were analytical grade.
Kunming mice (SPF Grade) weighing 18–22 g were obtained
from the Experimental Center of Chinese Academy of MedicalFigure 1 Chemical structures ofSciences and housed at a constant temperature of 22–25 1C under
a 12 h light–dark cycle with free access to food and drinking
water. The protocol was approved by the Institutional Animal
Care and Use Committee of Tsinghua University (Beijing, China).
2.2. Analytical conditions and sample pretreatment procedure
Analytical LC was performed with a Hitachi (Japan) system
comprising of pump (L-2130), UV detector (L-2400), auto-
sampler (L-2200), and column oven (L-2300) connected to a
computer installed with appropriate software. Reversed-phase
chromatographic separation was performed on a 250 mm
4.60 mm, 5 mm particle, Phenomenex RP-18C column with
a mobile phase gradient prepared from pure acetonitrile
(component A) and 0.3% aqueous formic acid (component
B). The LC gradient program was: 0.01–10 min, 78% (v/v) B;
10–12 min, 78–60% B; 12–14 min, 60–50% B; 14–15 min,
50–40% B; 15–20 min, 40% B; 20–25 min, 40–78% B;
25–30 min, 78% B. The ﬂow rate was 0.8 mL/min, the
injection volume was 20 mL, the detection wavelength was
335 nm, and the column temperature was 40 1C.
To each tissue sample, 20 mL of IS solution was added to
make a concentration of 0.1 mg/mL, followed by 50 mL of 1:20
phosphate solution and 5 mL of methanol, then vigorously
vortexed for 3 min and centrifuged at 10,000 rpm for 15 min.
The supernatant was transferred to a new centrifuge tube and
evaporated to dryness under a stream of nitrogen gas at 40 1C.
The residue was reconstituted in 100 mL mobile phase, and
then mixed for 3 min through vortexing followed by the
centrifugation at 10,000 rpm for 15 min. The supernatant
was transferred to an inner glass sample tube and 20 mL of
supernatant was injected for analysis.
2.3. Tissue distribution examination
Kunming mice were divided into eight groups with 10 mice in
each group, and fasted for 12 h prior to intravenous adminis-
tration of scutellarin at a dose of 144 mg/kg (or 7e at a dose
of 799 mg/kg). Tissues were collected at 5, 15, 30, 45, 60, 90, 120
and 240 min following drug administration. Various tissues
(brain, heart, liver and spleen) were immediately harvested and
kept in normal saline to remove the blood. After blotted on
ﬁlter paper, the ﬁlter paper with sample blot was weighted. In
addition, after homogenization using a 3-fold volume of normal
saline in 10 mL centrifuge tube, tissue samples were stored at
80 1C until assay16.
2.4. Statistical analysis
The AUC0t, Cmax, MRT and T1/2 were calculated by Data
and MAX Statistics (DAS 2.0, Shanghai, China). Statisticalscutellarin and its prodrug 7e.
Juan Lu et al.276analysis was performed using Student’s t-test. A signiﬁcant
difference was considered at Po0.05.3. Results and discussion
In the previous study it was demonstrated that the prodrug 7e
has a protective effect on ischemic injury induced by cerebral
I/R compared to that obtained with the parent drug, scutel-
larin. In order to characterize the protective effect of PEGy-
lated scutellarin on cerebral I/R injury in rats, the distribution
of 7e and scutellarin in tissues after injection was determined
at designated time intervals. The concentration–time curves
of 7e and scutellarin in various tissues are shown in Fig. 2.
The relative uptake efﬁciencies (REs) of 7e in the tissues of
mice were calculated as the ratio of AUC0t for 7e to AUC0t
for scutellarin in the same tissue17 (Table 1).
The results show that (i) the highest levels of 7e and
scutellarin were observed in all tissues at 5 min post-adminis-
tration (Fig. 2); (ii) although the concentration of 7e in various
tissues exhibited a gradual decrease, the scutellarin releasedFigure 2 Concentration proﬁles of scutellarin and 7e in brain, heart, li
Table 1 Pharmacokinetic parameters of scutellarin and 7e in tis
Brain Heart
Scu 7e Scu 7e
AUC0-t (mg/mL min) 16.0770.56 179.2678.34
n 25.4571.99 11
MRT (min) 14.1670.32 27.771.21 21.2370.83 21
Cmax (mg/mL) 0.6870.08 5.2270.12 0.9270.05 4.
T1/2 (min) 12.5571.38 12.6670.72 14.5271.23 16
REs – 2.1 – 0.
nPo0.05 with respect to the pharmacokinetic parameter of scutellarfrom 7e could not be detected in tissues, which was probably
due to the low concentration of 7e in tissues, and even the
much lower concentration of scutellarin released from 7e.
Another possible reason was due to the quick degradation or
short half life of scutellarin. Pharmacokinetic studies showed
that the elimination half-life of scutellarin in dog plasma
was 1.0 min, which might be attributed to the cleavage of the
glycoside bond18. In contrast, scutellarin released from 7e is
detectable in plasma due to the high concentration of 7e1. (iii)
As shown in Table 1, on the basis of AUC, the distribution of
7e in brain was approximately 2.1-fold higher than that of
scutellarin, indicating that PEGylation resulted in greater
distribution into the brain. Because of the strong polarity
and insolubility in lipid, scutellarin does not readily cross
the blood–brain barrier (BBB). The modiﬁcation of scutellarin
with mPEG could effectively decrease the polarity and improve
the solubility due to the ﬂexible segment of mPEG and its
amphiphilic properties. As a result, the 7e can cross the BBB
much more easily than the parent drug. This greater distribution
into the brain may explain the more effective protection on
cerebral I/R injury in mice with 7e. (iv) Compared withver and spleen after intravenous dosing of scutellarin or 7e in mice.
sues after a single dose of scutellarin or 7e in mice (n¼10).
Liver Spleen
Scu 7e Scu 7e
1.1474.32 80.4773.17 1578.15713.96n – 66.0173.22
.1570.37 46.1871.10 50.3972.38 - 20.6670.84
3870.47 1.2670.11 28.2772.24 – 2.5570.27
.4771.02 0.9070.03 24.1571.47 – 0.7070.04
8 – 3.7 – –
in (Scu) in the same tissue.
Tissue distribution and pharmacokinetics of mPEG-scutellarin prodrug 277scutellarin, 7e shows greater accumulation in liver and spleen.
The level of 7e in liver was increased by approximately
3.7-fold after intravenous administration. Due to the large
molecular size of 7e phagocytosis may be improved which may
lead to the accumulation in liver and spleen.4. Conclusions
In this paper, the distribution of 7e and scutellarin after
intravenous administration in tissues was determined. The
distribution of 7e in brain was approximately 2.1-fold higher
than that of scutellarin, indicating that the slower elimination
in blood promoted better accessibility of 7e to the brain and
PEGylation facilitated uptake across the blood–brain barrier.
Presumably 7e was hydrolyzed and/or chemically transformed
to release scutellarin so as to exert its protective effect on
cerebral I/R injury in mice. This study also provided a simple
and convenient method to identify and quantitatively evaluate
drugs with these cerebrovascular protective properties.
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